Cost of hesitation just flipped: management describes buyers no longer able to wait out the decision
The model's full reasoning — Q4 2017 call → NOWe need answer YES or NO based on transcript. Need determine if management describes that buyers have recently lost ability to postpone decision, cost of delay risen, and real behavior showing business. Let's analyze. Transcript: Pacira Pharmaceuticals EXPAREL, opioid alternative. Management discusses opioid epidemic, partnerships, J&J, CMS reimbursement, etc. Need see if they describe buyers (hospitals, payers, surgeons) facing recent change making waiting costly, and decisions landing. They talk about opioid crisis, pressure to reduce opioids, CMS reimbursement changes, commercial payers recognizing economic advantage, moving inpatient to outpatient. But is there a "cost of delay" on buyer side? They mention "only thing that really limits access is financial constraints of hospital customers" and CMS reimbursement. They are working to get separate reimbursement. They say "Securing separate reimbursement for EXPAREL would create significant opportunity." Not necessarily buyers forced to decide now. They mention "opioid crisis" and "national survey" but that's societal. They mention partnerships with payers, hospitals. But do they say buyers can no longer wait? Not really. They describe growth, J&J partnership, education. They mention "we are working with CMS policymakers to achieve off-cycle change" and "if we are granted a code" future. They say "commercial payers already recognize economic advantage" and "supporting enhanced recovery after surgery protocols" but that's value proposition. No explicit "cost of waiting" for buyers. They mention "opioid epidemic" as urgency, but that's external pressure, not necessarily recent change in buyer's cost of delay. They mention "President's Opioid Commission" recommendations, but not that buyers are forced to act now. They mention "we are seeing wins" but not due to cost of delay. They mention "we have a list of hospitals where the only person that has relationships... have been non-EXPAREL employee" but that's J&J. No. Question asks: Does management convey that waiting, deferring, sticking with status quo has become materially more expensive/risky for counterparties recently, and buying decisions forced? I don't see that. They talk about opioid epidemic, but that's not specifically about buyers' cost of delay. They talk about "opioid-sparing" as important, but not that hospitals face penalties for not adopting.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
PFIE · Q1 2023 → YESThe question is about whether management describes that buyers have recently lost the ability to postpone decisions, making waiting more expensive or risky, forcing buying decisions now, and showing c...YES Management describes a clear shift where buyers' deferred maintenance and retrofits—previously postponed—have now become urgent due to pent-up demand and catch-up efforts, with recent behavior showing these decisions are being forced now, and the broader market opportunity still largely ahead.
BFIN · Q1 2022 → YESThe question is about whether management describes that buyers have recently lost the ability to postpone decisions, making waiting more expensive or risky, and this is already producing business, wit...
HNRG · Q3 2021 → YESThe question is about whether management describes that buyers have recently lost the ability to postpone decisions, making waiting more expensive or risky, forcing buying decisions, and showing curre...